Halyna Buvailo, PhD

ReCode Therapeutics, a leader in genetic medicines, is pioneering a promising avenue in the treatment of primary ciliary dyskinesia (PCD) with its latest clinical trial involving RCT1100, a groundbreaking mRNA-based therapy. This novel approach is the first of its kind to be clinically evaluated for restoring ciliary function in individuals affected by PCD, particularly those with mutations in the DNAI1 gene.

InVivo Biosystems, operating in the realm of CRISPR-edited animal models for biomedical research, has recently embarked on a new phase of growth and innovation. The Eugene, Oregon-based company has secured a notable $3 million investment, a collaborative effort led by Rogue Venture Partners with significant contributions from Portland Seed Fund, ONAMI, and Launch Oregon. This influx of capital is earmarked for the acceleration of CRISPR technology commercialization, positioning InVivo Biosystems at the forefront of advancements in drug discovery.

In a new development in the field of dermatological therapeutics, SiSaf Ltd, a biopharmaceutical company based in Guildford, UK, has reached a pivotal stage for its novel treatment for alopecia areata. The company, renowned for its work in RNA therapeutics for rare diseases, announced the completion of patient enrollment for a Phase II clinical trial. This trial is notable for its focus on a treatment for mild-to-moderate alopecia areata using SiSaf’s proprietary Bio-Courier delivery technology.

Iktos, a French AI-focused company specializing in new drug design, and Curreio, a Japanese cryo-electron microscopy (cryo-EM) expert, have recently entered into a collaboration agreement. The partnership aims to leverage the power of artificial intelligence (AI) and cryo-EM technology to expedite the discovery and design of novel preclinical drug candidates for an undisclosed therapeutic target.

Nuritas, an innovator in AI-based peptide discovery from natural sources, has announced the results of a second clinical trial on its patented ingredient, PeptiStrong™. The ingredient, which is sourced from plants and discovered using Nuritas' exclusive AI peptide-discovery platform, has been shown to be the most effective solution ever discovered for muscle function. The latest clinical trial, which was published in Nutrients and performed in the Sports Surgery Clinic Dublin, demonstrated that PeptiStrong™ is a unique multi-faceted solution whose action at the root cause of muscle health and muscle ageing could benefit multiple industries and various consumer profiles.

Gandeeva Therapeutics, a precision medicine company specializing in designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, has announced a new research collaboration with Moderna Inc. The partnership aims to explore the potential applications of Gandeeva's cutting-edge technology platform for one of Moderna's undisclosed programs.

As we delve deeper into the uncharted territories of biotechnology, the convergence of artificial intelligence (AI) and cryo-electron microscopy (Cryo-EM) has emerged as a powerful partnership for unlocking complex biological structures. In this blog post, we'll explore how AI is enabling Cryo-EM, enhancing our understanding of molecular architecture, and accelerating drug discovery. We'll also spotlight some pioneering companies developing Cryo-EM technology, and integrating AI to transform the field.